Envestnet Asset Management Inc. Buys 83,341 Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN)

Envestnet Asset Management Inc. raised its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 15.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 618,691 shares of the medical equipment provider's stock after buying an additional 83,341 shares during the quarter. Envestnet Asset Management Inc. owned about 0.14% of Smith & Nephew SNATS worth $17,552,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Hexagon Capital Partners LLC grew its stake in Smith & Nephew SNATS by 63.3% during the 1st quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock valued at $30,000 after purchasing an additional 406 shares during the last quarter. National Bank of Canada FI raised its holdings in Smith & Nephew SNATS by 36.5% in the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock worth $41,000 after purchasing an additional 446 shares during the period. Bessemer Group Inc. raised its holdings in shares of Smith & Nephew SNATS by 3,471.4% during the first quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock valued at $49,000 after acquiring an additional 1,701 shares during the last quarter. Hara Capital LLC raised its holdings in shares of Smith & Nephew SNATS by 391.4% during the fourth quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock valued at $60,000 after acquiring an additional 1,957 shares during the last quarter. Finally, Opal Wealth Advisors LLC purchased a new position in Smith & Nephew SNATS during the first quarter worth approximately $73,000. Hedge funds and other institutional investors own 25.64% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. HSBC cut Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Canaccord Genuity Group increased their target price on Smith & Nephew SNATS from $27.00 to $28.00 and gave the stock a "hold" rating in a research note on Thursday, May 1st. Finally, Hsbc Global Res cut Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Six equities research analysts have rated the stock with a hold rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $28.00.

Smith & Nephew SNATS Trading Up 0.3%

NYSE SNN traded up $0.09 during trading hours on Monday, hitting $30.26. The company's stock had a trading volume of 718,639 shares, compared to its average volume of 818,492. The stock has a fifty day moving average of $29.48 and a 200 day moving average of $27.68. The company has a quick ratio of 1.33, a current ratio of 2.89 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $13.25 billion, a P/E ratio of 14.01, a PEG ratio of 0.92 and a beta of 0.69. Smith & Nephew SNATS, Inc. has a twelve month low of $23.69 and a twelve month high of $31.72.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.